TriLink BioTechnologies® Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea
04 October 2021 - 11:30PM
TriLink BioTechnologies (“TriLink”), a Maravai LifeSciences company
(Nasdaq: MRVI) and a leader in the production of nucleic acids for
research, diagnostics and therapeutics applications, announced
today that it expects to supply its proprietary CleanCap® mRNA
capping technology and the modified nucleoside, uridine
triphosphate, to EyeGene, Inc. (“EyeGene”) for production of
EyeGene’s mRNA COVID-19 vaccine, EG-COVID, which recently received
approval to begin clinical trials from the South Korean Ministry of
Food and Drug Safety (MFDS). This collaboration with EyeGene is
expected to represent the first clinical-stage program to use
GMP-grade modified uridine triphosphate, with an intended use for
further processing, manufactured by TriLink.
“COVID-19 is one of the greatest challenges our
industry has faced. We have been inspired by the ingenuity and
tenacity with which the world has tackled the pandemic and are
proud to be supporting important efforts to develop new vaccine
approaches and expand access to COVID-19 vaccines globally,” said
Brian Neel, Chief Operating Officer of TriLink BioTechnologies. “As
part of these efforts, TriLink is excited to be expanding its
collaboration with EyeGene in South Korea. We look forward to
continuing to support them through their clinical trials,
manufacturing scale up efforts and commercialization.”
Dr. H. Christian Hong, EyeGene’s Chief Business
Officer added, "The pandemic is still raging around the world, and
we are eager to begin clinical trials with EG-COVID. Our scientists
have used a cationic liposome-based delivery system for the
vaccine, and we are very confident in its safety and effectiveness.
TriLink’s CleanCap technology and modified uridine triphosphate, in
combination with the mRNA manufacturing platform, has enabled
EyeGene to reach the clinic quickly."
TriLink and EyeGene met on September 21, 2021,
at the KORUS Global Vaccine Business Roundtable held in New York,
to discuss their continued collaboration as EyeGene advances
development of its vaccine into phase 1 clinical testing and
beyond.
Mr. Neel commented further, “In addition to
providing a forum to meet with EyeGene, the KORUS vaccine
roundtable gave us an opportunity to engage with other leaders
within the global supply chain for vaccine manufacturing,
particularly those suppliers with active efforts in the Asia
Pacific region. As an example, TriLink partnered with leading
global enzyme supplier New England Biolabs® to supply reagents for
mRNA manufacturing in support of Eye Gene’s phase 1 studies. We
look forward to continuing to partner with vaccine developers and
manufacturers in the region and to bringing forward potential new
mRNA vaccines that may help expand access and provide new tools in
the fight against the COVID-19 pandemic and for other
indications.”
About CleanCap®CleanCap® is
TriLink’s market-leading co-transcriptional mRNA capping technology
which we believe offers a number of key features and benefits
compared to enzymatic capping products. We believe CleanCap enables
higher yield, more bioavailable end product and enables customers
to produce vaccines faster and at a lower cost.
About EG-COVIDEG-COVID will
undergo a Phase 1/2a clinical trial to test the safety,
tolerability, and immunogenicity of the vaccine. The vaccine uses a
cationic liposome-based vaccine delivery system and is produced in
a freeze-drying formula. It is refrigerated at 2–8 ℃ for
preservation and is thus competitive for export to foreign markets
with insufficient low-temperature refrigeration facilities.
About TriLink
BioTechnologiesTriLink BioTechnologies, part of Maravai
LifeSciences, is a CDMO helping life science leaders and innovators
overcome challenges in the synthesis and scale-up of nucleic acids,
NTPs and mRNA capping analogs with scale-up expertise and unique
mRNA production capabilities, including its proprietary
CleanCap® mRNA capping technology. TriLink continues to expand
its cGMP and general manufacturing capacity at its new global
headquarters to support mRNA, oligonucleotide & plasmid
therapeutic, vaccine and diagnostic customers. For more
information about TriLink, visit
www.trilinkbiotech.com.
About Maravai
LifeSciencesMaravai is a leading life sciences company
providing critical products to enable the development of drug
therapies, diagnostics, novel vaccines, and support research on
human diseases. Maravai's companies are leaders in providing
products and services in the fields of nucleic acid synthesis,
bioprocess impurity detection and analysis, and protein labeling
and detection to many of the world's leading biopharmaceutical,
vaccine, diagnostics, and cell and gene therapy companies. For more
information about Maravai LifeSciences,
visit www.maravai.com.
About EyeGeneEyeGene took its first step in the
development of innovative biopharmaceutical drugs when it was first
established in June 2000. Since then, EyeGene's R&D Scientists
have continued to research and develop innovative drugs for the
treatment and prevention of age-related diseases. For more
information about EyeGene,
visit eyegene.co.kr/kor/.
Forward-looking Statements This
press release contains “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Investors are cautioned
that statements in this press release which are not strictly
historical statements constitute forward-looking statements,
including, without limitation, statements regarding EyeGene’s
continued use of CleanCap and modified UTP manufactured by TriLink,
our ability to develop new partnerships, and the benefits of
CleanCap compared with enzymatic capping methods, constitute
forward-looking statements and are identified by words like “aim,”
“believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,”
“look forward,” or “could” and similar expressions. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including, without limitation and
uncertainties related to the level of demand for our products and
services, continued validation of the safety and effectiveness of
our technology, new scientific developments and competition from
other products. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in our Annual Report on Form 10-K for the year ended December 31,
2020, as well as other documents on file with the Securities and
Exchange Commission. Actual results may differ materially from
those contemplated by these forward-looking statements, and
therefore you should not rely upon them. These forward-looking
statements reflect our current views and we do not undertake to
update any of these forward-looking statements to reflect a change
in its views or events or circumstances that occur after the date
hereof except as required by law.
Contact Information :
Media Contact : Sara Michelmore
MacDougall Advisors
+1 781-235-3060
maravai@macbiocom.com
Investor Contact: Deb Hart
Maravai Life Sciences
+ 1 858-988-5917
ir@maravai.com
EyeGene Contact : H. Christian Hong
+82-70-4066-1798
armygreen@eyegene.co.kr
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Apr 2024 to May 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From May 2023 to May 2024